Investment Thesis
Vivos Therapeutics is in severe financial distress with negative stockholders' equity (-$1.1M), a critical liquidity crisis (0.27x current ratio), and unsustainable cash burn of $6M annually against only $2.1M in cash reserves, implying sub-5-month runway. While gross margins of 59.5% demonstrate product viability, the company loses $1.51 for every dollar of revenue with deep operating losses (-128.7% margin) and cannot service its obligations.
Strengths
- Healthy gross margin of 59.5% indicates product/service quality and pricing power
- Revenue growth of 16% YoY shows some market traction despite financial distress
- Minimal capital expenditure requirements ($18K) suggests asset-light business model
Risks
- Negative stockholders' equity of -$1.1M indicates technical insolvency and existential solvency risk
- Critical liquidity crisis with current ratio of 0.27x; liabilities exceed current assets by 73%
- Cash runway of approximately 4-5 months at current $6M annual operating cash burn rate with only $2.1M in cash
- Operating losses of $6.6M on $5.1M revenue indicate unsustainable unit economics requiring immediate restructuring
- Negative operating cash flow of -$6M vastly exceeds revenue, unsustainable without capital infusion or dramatic cost reduction
Key Metrics to Watch
- Cash balance trend and monthly burn rate (critical solvency indicator)
- Operating cash flow and path to breakeven (company must dramatically reduce losses)
- Revenue growth sustainability and gross profit expansion (must offset operating expenses)
- Debt covenant compliance and refinancing needs (bankruptcy risk if breached)
- Insider transaction patterns (Form 4 filings may signal management confidence or distress)
Financial Metrics
Revenue
5.1M
Net Income
-7.7M
EPS (Diluted)
$-0.52
Free Cash Flow
-6.0M
Total Assets
25.0M
Cash
2.1M
Profitability Ratios
Gross Margin
59.5%
Operating Margin
-128.7%
Net Margin
-149.4%
ROE
N/A
ROA
-30.7%
FCF Margin
-117.3%
Balance Sheet & Liquidity
Current Ratio
0.27x
Quick Ratio
0.27x
Debt/Equity
N/A
Debt/Assets
105.1%
Interest Coverage
-6.01x
Long-term Debt
617.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T09:40:26.191247 |
Data as of: 2026-03-31 |
Powered by Claude AI